World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Antimicrobial resistance is a major public health problem globally. Likewise, forms of tuberculosis (TB) resistant to first- and second-line TB medicines present a major challenge for patients, healthcare workers and healthcare services. In November 2019, the World Health Organization (WHO) convened an independent international expert panel to review new evidence on the treatment of multidrug- (MDR) and rifampicin-resistant (RR) TB, using the Grading of Recommendations Assessment, Development and Evaluation approach. Updated WHO guidelines emerging from this review, published in June 2020, recommend a shorter treatment regimen for patients with MDR/RR-TB not resistant to fluoroquinolones (of 9–11 months), with the inclusion of bedaquiline instead of an injectable agent, making the regimen all oral. For patients with MDR-TB and additional fluoroquinolone resistance, a regimen composed of bedaquiline, pretomanid and linezolid may be used under operational research conditions (6–9 months). Depending on the drug-resistance profile, extent of TB disease or disease severity, a longer (18–20 months) all-oral, individualised treatment regimen may be used. In addition, the review of new data in 2019 allowed the WHO to conclude that there are no major safety concerns on the use of bedaquiline for >6 months’ duration, the use of delamanid and bedaquiline together and the use of bedaquiline during pregnancy, although formal recommendations were not made on these topics. The 2020 revision has highlighted the ongoing need for high-quality evidence and has reiterated the need for clinical trials and other research studies to contribute to the development of evidence-based policy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A new tuberculosis treatment regimen for drug-resistant tuberculosis, endorsed by WHO, that is efficacious, safe, and shorter than previous regimens could have a role in reducing tuberculosis deaths.51”
From Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021 (2024) · cites this paper as [51]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
What is ‘quality of evidence’ and why is it important to clinicians?
Guyatt, G. H., Oxman, A. D., Kunz, R., Vist, G. E., Falck-Ytter, Y., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39490.551019.be · Cited by 3,250
Sustainable Development Goals: Law, Theory and Implementation
(2018) · Edward Elgar Publishing eBooks · doi:10.4337/9781786438768 · Cited by 1,925
The World Health Organization Global Action Plan for antimicrobial resistance
Mendelson, M., & Matsoso, M. P. (2015) · South African Medical Journal · doi:10.7196/samj.9644 · Cited by 1,155
Uplekar, M., Weil, D., Lonnroth, K., Jaramillo, E., Lienhardt, C., Dias, H. M., Falzon, D., Floyd, K., Gargioni, G., Getahun, H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60570-0 · Cited by 1,117
Self-citationTreatment of Highly Drug-Resistant Pulmonary Tuberculosis
Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., Mendel, C. M., Egizi, E., Moreira, J., Timm, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1901814 · Cited by 1,044
Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
Van Deun, A., Maug, A. K. J., Salim, M. A. H., Das, P. K., Sarker, M. R., Daru, P., & Rieder, H. L. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201001-0077oc · Cited by 647
Ahmad, N., Ahuja, S. D., Akkerman, O. W., Alffenaar, J.-W. C., Anderson, L. F., Baghaei, P., Bang, D., Barry, P. M., Bastos, M. L., Behera, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31644-1 · Cited by 632
Self-citationFinancial burden for tuberculosis patients in low- and middle-income countries: a systematic review
Tanimura, T., Jaramillo, E., Weil, D., Raviglione, M., & Lönnroth, K. (2014) · European Respiratory Journal · doi:10.1183/09031936.00193413 · Cited by 586
Self-citationTreatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
Research works printed but not linked: 1
- Dooley K , Rosenkranz S , Conradie F , et al. QT effects of bedaquiline, delamanid or both in MDR-TB patients: the DELIBERATE trial. Conference on Retroviruses and Opportunistic Infections (CROI). Washington, USA. March 4–7, 2019. Available from: https://www.croiconference.org/abstract/qt-effects-bedaquiline-delamanid-or-both-mdr-tb-patients-deliberate-trial/
Cited by
The WHO Global Tuberculosis 2021 Report – not so good news and turning the tide back to End TB
Chakaya, J., Petersen, E., Nantanda, R., Mungai, B. N., Migliori, G. B., Amanullah, F., Lungu, P., Ntoumi, F., Kumarasamy, N., Maeurer, M., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.011 · Cited by 405
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis
Nyang’wa, B.-T., Berry, C., Kazounis, E., Motta, I., Parpieva, N., Tigay, Z., Solodovnikova, V., Liverko, I., Moodliar, R., Dodd, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2117166 · Cited by 376
New developments in tuberculosis diagnosis and treatment
Gill, C. M., Dolan, L., Piggott, L. M., & McLaughlin, A. M. (2022) · Breathe · doi:10.1183/20734735.0149-2021 · Cited by 161
Ledesma, J. R., Ma, J., Zhang, M., Basting, A. V. L., Chu, H. T., Vongpradith, A., Novotney, A., LeGrand, K. E., Xu, Y. Y., Dai, X., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00007-0 · Cited by 146
“51 Additional research should examine the marked progress in reducing tuberculosis deaths in the 17 countries that achieved the End TB mortality milestone in 2020.”
World Health Organization treatment outcome definitions for tuberculosis: 2021 update
Nguyen, L. N., Viney, K. A., Gegia, M., Falzon, D., Glaziou, P., Floyd, K., Timimi, H., Ismail, N. A., Matteo Zignol, E., Kasaeva, T., et al. (2021) · European Respiratory Journal · doi:10.1183/13993003.00804-2021 · Cited by 141
Self-citation25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward
Dean, A. S., Auguet, O. T., Glaziou, P., Matteo Zignol, E., Ismail, N. A., Kasaeva, T., & Floyd, K. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00808-2 · Cited by 139
Self-citationDerendinger, B., Dippenaar, A., de Vos, M., Huo, S., Alberts, R., Tadokera, R., Limberis, J. D., Sirgel, F. A., Dolby, T., Spies, C., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00172-6 · Cited by 108
“28 Nevertheless, our study highlights the importance of fluoroquinolone drug-susceptible testing and suggests that protecting fluoroquinolone susceptibility is possibly essential to prevent emergence of bedaquiline resistance.”
Viney, K. A., Nguyen, L. N., Gegia, M., Matteo Zignol, E., Glaziou, P., Ismail, N. A., Kasaeva, T., & Mirzayev, F. (2021) · European Respiratory Journal · doi:10.1183/13993003.00361-2021 · Cited by 84
Self-citationExpert consensus statement on therapeutic drug monitoring and individualization of linezolid
Lin, B., Hu, Y., Xu, P., Xu, T., Chen, C., He, L., Zhou, M., Chen, Z., Zhang, C., Yu, X., et al. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.967311 · Cited by 88
“Reason Although linezolid was recommended in the revised version of World Health Organization Recommendations on the Treatment of Drug-Resistant Tuberculosis, 2020 Update, the optimal dosage for tuberculosis needs to be determined (75).”
Sharma, K., Ahmed, F., Sharma, T., Grover, A., Agarwal, M., & Grover, S. (2023) · ACS Omega · doi:10.1021/acsomega.2c05511 · Cited by 65
Xu, G., Liu, H., Jia, X., Wang, X., & Xu, P. (2021) · Tuberculosis · doi:10.1016/j.tube.2021.102083 · Cited by 71
Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date
Stancil, S. L., Mirzayev, F., & Abdel‐Rahman, S. M. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s281639 · Cited by 61
Self-citationIn silico design of a promiscuous chimeric multi-epitope vaccine against Mycobacterium tuberculosis
Andongma, B. T., Huang, Y., Chen, F., Tang, Q., Yang, M., Chou, S., Li, X., & He, J. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.01.019 · Cited by 65
“This chemotherapy cycle is very long, usually taking nine to twelve months, or even longer [5], which increases the risk of drug-resistant mutations in M.”
BackgroundTiberi, S., Vjecha, M. J., Zumla, A., Galvin, J., Migliori, G. B., & Zumla, A. I. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.02.067 · Cited by 65
Bergeron, A., Mikulska, M., Greef, J. D., Bondeelle, L., Franquet, T., Herrmann, J., Lange, C., Spriet, I., Akova, M., Donnelly, J. P., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00227-4 · Cited by 58
Mesoporous silica nanocarriers as drug delivery systems for anti-tubercular agents: a review
Tella, J. O., Adekoya, J. A., & Ajanaku, K. O. (2022) · Royal Society Open Science · doi:10.1098/rsos.220013 · Cited by 55
Pediatric Tuberculosis Management: A Global Challenge or Breakthrough?
Maphalle, L. N. F., Michniak‐Kohn, B. B., Ogunrombi, M. O., & Adeleke, O. A. (2022) · Children · doi:10.3390/children9081120 · Cited by 92
“Accordingly, through the prioritization of effectiveness and toxicity, a new drug classification that split medicines for drug-resistant TB into three groups (instead of four—A, B, C, and D as detailed above) is detailed below [149,150]:”
BackgroundCirculating microRNAs as emerging regulators of COVID-19
Liang, Y., Fang, D., Gao, X., Deng, X., Chen, N., Wu, J., Min De, Z. E. N. G., & Luo, M. (2022) · Theranostics · doi:10.7150/thno.78164 · Cited by 56
“COVID-19 was declared a global pandemic by the World Health Organization in March 2020 [2].”
BackgroundChowdhury, K., Ahmad, R., Sinha, S., Dutta, S., & Haque, M. (2023) · Cureus · doi:10.7759/cureus.35154 · Cited by 76
“Effective and comparatively low-risk medicines have been incorporated into the regimen [59,108].”
BackgroundDiriba, G., Alemu, A., Yenew, B., Tola, H. H., Gamtesa, D. F., Mollalign, H., Eshetu, K., Moga, S., Abdella, S., Tollera, G., et al. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.04.392 · Cited by 55
“In the past 20 years, DR-TB has spread across the world and continued to be a challenge to global TB control efforts [1].”
BackgroundYao, C., Guo, H., Li, Q., Zhang, X., Shang, Y., Li, T., Wang, Y., Xue, Z., Wang, L., Li, L., et al. (2021) · Antimicrobial Resistance and Infection Control · doi:10.1186/s13756-021-00995-8 · Cited by 40
“Although recent changes in the WHO recommendations for treatment of RR/MDR-TB patients have replaced injectables with bedaquiline in preferred therapy [17], the treatment of these patients majorly relies on long-course regimens stipulated by the WHO due to limited accessibility to bedaquiline.”
BackgroundTuberkulose im Erwachsenenalter
Schaberg, T., Brinkmann, F., Feiterna‐Sperling, C., Geerdes-Fenge, H. F., Hartmann, P., Häcker, B., Hauer, B., Haas, W., Heyckendorf, J., Lange, C. G., et al. (2022) · Pneumologie · doi:10.1055/a-1934-8303 · Cited by 42
Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis
Sweeney, S., Berry, C., Kazounis, E., Motta, I., Vassall, A., Dodd, M., Fielding, K., & Nyang’wa, B.-T. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001337 · Cited by 37
“BPaL regimens were recommended for use under operational research conditions by WHO in 2021 [5] following evidence from an open-label, single-arm study (Nix-TB) that BPaL led to favourable outcomes 6 months after treatment completion in populations with highly drugresistant TB (including treatment intolerant MDR-TB an…”
MethodHui, S. Y. A., & Lao, T. T.-H. (2022) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2022.07.006 · Cited by 43
Tuberculosis: The Past, the Present and the Future
Koegelenberg, C. F. N., Schoch, O. D., & Lange, C. G. (2021) · Respiration · doi:10.1159/000516509 · Cited by 48
Calcagno, A., Coppola, N., Sarmati, L., Tadolini, M., Parrella, R., Matteelli, A., Riccardi, N., Trezzi, M., Biagio, A. D., Pirriatore, V., et al. (2024) · Infection · doi:10.1007/s15010-024-02183-3 · Cited by 33
“Data in experimental animals and in patients with CF with bacterial infections suggest a good lung penetration and a rapid uptake by alveolar macrophages [94, 95].”
BackgroundBelete, T. M. (2022) · Microbiology Insights · doi:10.1177/11786361221099878 · Cited by 33
Nguyen, T. M. P., Le, T. H. M., Merle, C. S., Pedrazzoli, D., Nguyen, N. L., Decroo, T., Nguyen, H. B., Hoang, T. T. T., & Nhung, N. V. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.11.007 · Cited by 29
Kula, K., & Sadowski, M. (2023) · Chemistry of Heterocyclic Compounds · doi:10.1007/s10593-023-03175-1 · Cited by 29
Application of liposomes in the treatment of infectious diseases
Suhaimi, N. A. A., Ahmad, S., Husna, S. M. N., Sarmiento, M. E., Acosta, A., Norazmi, M. N., Ibrahim, J., Mohamud, R., & Kadir, R. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120734 · Cited by 33
Mariner-Llicer, C., Goig, G. A., Zaragoza‐Infante, L., Torres‐Puente, M., Villamayor, L. M., Navarro, D., Borrás, R., Chiner‐Oms, Á., & Comas, I. (2021) · Microbial Genomics · doi:10.1099/mgen.0.000740 · Cited by 27
Actualización del diagnóstico y tratamiento de la tuberculosis
Baquero‐Artigao, F., del Rosal, T., Falcón-Neyra, L., Ferreras-Antolin, L., Gómez‐Pastrana, D., Hernanz‐Lobo, A., Méndez-Echevarría, A. M., Noguera‐Julián, A., Sánchez, M. T. P., Rodríguez-Molino, P., et al. (2023) · Anales de Pediatría · doi:10.1016/j.anpedi.2023.03.011 · Cited by 26
“Tabla 5 Fármacos antituberculosos de segunda línea cate-gorizados según la prioridad en su 48,52 ◦ Las decisiones sobre el esquema a administrar deben tomarse según el criterio clínico del profesional responsable y las preferencias del paciente y su familia, considerando los siguientes aspectos:…”
BackgroundWang, J., Nie, W., Ma, L., Li, Q., Geng, R., Shi, W., & Chu, N. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s425743 · Cited by 26
“tuberculosis strains are also resistant to one or more other anti-TB drugs.(2) More novel anti-TB drugs and/or regimens are being developed and introduced into clinical practice to address the emerging MDR/RR-TB.”
BackgroundMerchant, S. A., Shaikh, M. J. S., & Nadkarni, P. M. (2022) · World Journal of Radiology · doi:10.4329/wjr.v14.i6.114 · Cited by 34
Unlocking InhA: Novel approaches to inhibit Mycobacterium tuberculosis
Wahan, S. K., Bhargava, G., Chawla, V., & Chawla, P. A. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107250 · Cited by 24
Admassu, F., Abera, E., Gizachew, A., Sedoro, T., & Gari, T. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-061836 · Cited by 24
Alene, K. A., Murray, M. B., van de Water, B. J., Becerra, M. C., Atalell, K. A., Nicol, M. P., & Clements, A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.16527 · Cited by 23
Wang, C., Wang, G., Huo, F., Xue, Y., Jia, J., Dong, L., Zhao, L., Wang, F., Huang, H., & Duan, H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1067516 · Cited by 21
“Linezolid (LZD) is the first oxazolidinone drug that is used in TB treatment and has been recommended by WHO as the core drug (group A) for the treatment of drug-resistant TB (2).”
BackgroundParticulate Mycobacterial Vaccines Induce Protective Immunity against Tuberculosis in Mice
Chen, S., Quan, D. H., Wang, X. T., Sandford, S., Kirman, J. R., Britton, W. J., & Rehm, B. H. A. (2021) · Nanomaterials · doi:10.3390/nano11082060 · Cited by 22
“The spread of drug-resistant forms of TB is a growing threat to global public health [5,6].”
BackgroundParums, D. V. (2021) · Medical Science Monitor · doi:10.12659/msm.934292 · Cited by 19
“The oral drug treatment regimens may be individualized based on the severity of TB and the MDR TB molecular profile [11,12].”
BackgroundMethodInfluentialZhao, B. T., Liu, C., Fan, J., Ma, A., He, W., Hu, Y., & Zhao, Y. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02405-21 · Cited by 18
Li, S., Tan, Y., Deng, Y., Bai, G., Huang, M., Shang, Y., Wang, Y., Xue, Z., Zhang, X., Wang, W., et al. (2023) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2023.11.018 · Cited by 18
Wang, L., Mai, Y., Zhang, J., Ruan, C., Hu, J. P., Ye, K., He, Y., Wang, D., Jin, L., Mao, Z., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.159666 · Cited by 19
Zhou, W., Yang, B., Zou, Y., Rahman, K., Cao, X., Lei, Y., Lai, R., Fu, Z. F., Chen, X., & Cao, G. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.658637 · Cited by 17
Heysell, S. K., Mpagama, S. G., Огарков, О. Б., Conaway, M. R., Ahmed, S., Николаевна, Ж. С., Pholwat, S., Al‐Shaer, M. H., Chongolo, A. M., Mujaga, B., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac511 · Cited by 17
“to shorten the treatment duration or improve treatment efficacy with combinations of re-prioritized drugs 9 [4].”
BackgroundKebede, B., Belay, W. Y., Abebe, D., Tegegne, B. A., & Belayneh, A. (2022) · SAGE Open Medicine · doi:10.1177/20503121221094191 · Cited by 19
Du, W., Zhao, Y., Zhang, L., Che, J., Liu, Z., Li, K., & Che, N. (2022) · BMC Microbiology · doi:10.1186/s12866-022-02698-5 · Cited by 17
Assay development and inhibition of the Mt-DprE2 essential reductase from Mycobacterium tuberculosis
Batt, S. M., Toth, S., Rodríguez, B., Abrahams, K. A., Veerapen, N., Chiodarelli, G., Cox, L. R., Moynihan, P. J., Lelièvre, J., Fütterer, K., et al. (2023) · Microbiology · doi:10.1099/mic.0.001288 · Cited by 17
“Many of the current first- and second- line drugs have been in circulation for over 50 years, with resistant strains rife, in the form of MDR (multidrug- resistant) and XDR (extremely drug- resistant) strains [2].”
BackgroundUpdate on the diagnosis and treatment of tuberculosis
Baquero‐Artigao, F., del Rosal, T., Falcón-Neyra, L., Ferreras-Antolin, L., Gómez‐Pastrana, D., Hernanz‐Lobo, A., Méndez-Echevarría, A. M., Noguera‐Julián, A., Sánchez, M. T. P., Rodríguez-Molino, P., et al. (2023) · Anales de Pediatría (English Edition) · doi:10.1016/j.anpede.2023.03.009 · Cited by 17
Haq, S. U., Ling, W., Aqib, A. I., Danmei, H., Aleem, M. T., Fatima, M., Ahmad, S., & Gao, F. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177511 · Cited by 26
QT prolongation in the STREAM Stage 1 Trial
Hughes, G., Bern, H., Chiang, C.-Y., Goodall, R. L., Nunn, A., Rusen, I. D., & Meredith, S. K. (2022) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.21.0403 · Cited by 17
Risk factors for multidrug resistance in tuberculosis patients with diabetes mellitus
Li, S., Liang, Y., & Hu, X. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07831-3 · Cited by 17
“MDR TB is defined as tuberculosis that is resistant to at least both rifampicin and isoniazid [7].”
BackgroundAssessing the safety of bedaquiline: insight from adverse event reporting system analysis
Wu, J., Pan, H., Shen, L., & Zhao, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1382441 · Cited by 16
Sukmawati, E., Marzuki, K., Batubara, A., Harahap, N. A., Efendi, E., & Weraman, P. (2023) · Jurnal Obsesi Jurnal Pendidikan Anak Usia Dini · doi:10.31004/obsesi.v7i4.4846 · Cited by 16
“Data submitted by the World Health Organization (WHO) on the prevalence of stunting in children under five years of age or toddlers, which reached around 149 million children in 2020, illustrated an urgent global challenge in the field of child nutrition (Mirzayev et al., 2021).”
BackgroundTreatments of Multidrug-Resistant Tuberculosis: Light at the End of the Tunnel
Lange, C., Barry, C. E., & Horsburgh, C. R. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202202-0393ed · Cited by 16
“The first clinical trial for a regimen to treat MDR-TB based on a novel antituberculosis medicine was initiated in 2007 (5), and we now find ourselves in the enviable position of having aWorld Health Organization–endorsed 9-month oral regimen for MDR-TB and a 6-month oral regimen for extensively drug-resistant TB (6)…”
BackgroundVadakunnel, M. J., Nehru, V. J., Brammacharry, U., Ramachandra, V., Palavesam, S., Muthukumar, A., Mani, B. R., R, S. S., Pradhabane, G., Dusthackeer, A., et al. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-10655-6 · Cited by 15
“Drug resistance is the primary cause of treatment failure in TB [7], but genomic studies indicate that other bacterial factors may also contribute.”
Kazakova, O. B., Racoviceanu, R., Petrova, A. V., Mioc, M., Militaru, A., Udrescu, L., Udrescu, M., Voicu, A., Cummings, J. E., Robertson, G. T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212542 · Cited by 16
Comparative genomics of drug-resistant strains of Mycobacterium tuberculosis in Ecuador
Gabriel Morey-León, G., Andrade-Molina, D., Fernández‐Cadena, J. C., & Berná, L. (2022) · BMC Genomics · doi:10.1186/s12864-022-09042-1 · Cited by 15
“The increased resistance to fluoroquinolones, also recently reported in other studies [80], is of concern, probably caused by the increased administration of this drug without prescription [81].”
BackgroundMisra, R., Kesarwani, V., & Nath, A. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-044096 · Cited by 14
Ethambutol optic neuropathy in the extended anti-tubercular therapy regime: A systematic review
Sabhapandit, S., Gella, V., Anumula, S., Thankachan, L., Ismail, M., Rao, R., & Talukdar, R. (2023) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1920_22 · Cited by 14
Impact of the revised definition of extensively drug-resistant tuberculosis
Véziris, N., Bonnet, I., Morel, F., Guglielmetti, L., Maitre, T., Ray, L. F. L., Sougakoff, W., Robert, J., & Aubry, A. (2021) · European Respiratory Journal · doi:10.1183/13993003.00641-2021 · Cited by 14
Yang, M. J., Zhan, S., Fu, L., Wang, Y., Zhang, P., & Deng, G. (2022) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2022.01025 · Cited by 14
Bottlenecks and opportunities in antibiotic discovery against Mycobacterium tuberculosis
Craggs, P. D., & de Carvalho, L. P. S. (2022) · Current Opinion in Microbiology · doi:10.1016/j.mib.2022.102191 · Cited by 15
Bakali, J. E., Błaszczyk, M., Evans, J. C., Boland, J. A., McCarthy, W. J., Fathoni, I., Dias, M. V. B., Johnson, E. O., Coyne, A. G., Mizrahi, V., et al. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202300221 · Cited by 13
Design, synthesis and anti-Tb evaluation of chalcone derivatives as novel inhibitors of InhA
Dhivya, L. S., Kathiravan, M. K., & Thamilselvan, G. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2227711 · Cited by 14
“Furthermore, bacterial strains resistant to all currently available TB medications have recently been reported in Iran, India, China, South Africa, and Italy, creating totally drug-resistant (TDR) TB (Ausi et al., 2021; Mirzayev et al., 2021).”
BackgroundChen, Y., Jiang, Q., Mijiti, P., Takiff, H. E., & Gao, Q. (2023) · eLife · doi:10.7554/elife.84815 · Cited by 15
Alawi, M., Alserehi, H., Ali, A. O., Al-Balawi, A. M., Alanizi, M. K., Nabet, F. M., Alkamaly, M. A., Assiri, A. M., Jokhdar, H., Qutub, M., et al. (2024) · Saudi Medical Journal · doi:10.15537/smj.2024.45.1.20230424 · Cited by 13
“26,27 Furthermore, patients with resistant or MDR strains have a greater risk of treatment failure and endure more extended treatment.”
BackgroundMechanism underlying linezolid-induced peripheral neuropathy in multidrug-resistant tuberculosis
Yuan, Y., Li, J., Chen, Y., Cai, Q., Xu, Y., Lin, L., Lang, Y., Guo, S., Zhang, R., & Cai, X. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.946058 · Cited by 13
“This suggests that patients with MDR-TB require, in theory, 18–20 months of linezolid administration (Mirzayev et al., 2021).”
BackgroundQiao, J., Yang, L., Feng, J., Dai, X., Xu, F., & Xia, P. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.020 · Cited by 15
Application of antimicrobial drugs in Mycobacterium tuberculosis and research progress
Wang, Y., Cao, D., & Liu, G. (2025) · Microbial Pathogenesis · doi:10.1016/j.micpath.2025.107794 · Cited by 13
Oderinlo, O. O., Jordaan, A., Seldon, R., Isaacs, M. L., Hoppe, H. C., Warner, D. F., Tukulula, M., & Khanye, S. D. (2023) · ChemMedChem · doi:10.1002/cmdc.202200572 · Cited by 18
Lv, X., Li, Y., Cai, B., He, W., Wang, R., Chen, M., Pan, J., & Hou, D. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s435984 · Cited by 12
“16 In addition, the standardized duration of bedaquiline (a Group A anti-tuberculosis agent) was recommended to be 24 weeks, according to the WHO guidelines.”
MethodLinezolid-induced lactic acidosis
Ramesh, V., Gattu, S., Maqsood, M., & Rao, V. P. (2024) · BMJ Case Reports · doi:10.1136/bcr-2023-259335 · Cited by 12
Nagarajan, K., Kumarswamy, K., Begum, R., Panibatla, V., Singarajipura, A., Adepu, R., Munjattu, J. F., Sellappan, S., Arangba, S., Goswami, A., et al. (2024) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2024.100372 · Cited by 13
Augustin, L., & Agarwal, N. (2023) · Gene · doi:10.1016/j.gene.2023.147173 · Cited by 13
Recent Updates on the Antimicrobial Compounds from Marine‐Derived Penicillium fungi
Li, H., Fu, Y., Song, F., & Xu, X. (2023) · Chemistry & Biodiversity · doi:10.1002/cbdv.202301278 · Cited by 12
Current landscape of exosomes in tuberculosis development, diagnosis, and treatment applications
Sun, X., Li, W., Zhao, L., Fan, K., Qin, F., Shi, L., Gao, F., & Zheng, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1401867 · Cited by 20
Xiong, Y., Yao, Y., Li, Y., Chen, S., Li, Y., Lin, K., & Li, X. (2025) · International Journal for Equity in Health · doi:10.1186/s12939-024-02368-0 · Cited by 17
Protein Cofactor Mimics Disrupt Essential Chaperone Function in Stressed Mycobacteria
Nelson, B., Hong, S. H., & Lupoli, T. J. (2022) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00651 · Cited by 11
Nguyen, T. M. P., Nguyen, B. H., Hoang, T. T. T., Nguyen, H. A., Vu, D. H., Nguyen, M. H., Nguyen, B. N., Decroo, T., & Nguyen, V. N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1023704 · Cited by 11
“Over the last decade, WHO has issued a number of new guidelines for the management of RR-TB in order to improve the outcome and tolerability of RR-TB treatment regimens (World Health Organization, 2013; World Health Organization, 2014; World Health Organization, 2015; World Health Organization, 2016a; World Health Org…”
BackgroundMulti-omics Investigation into the Mechanism of Action of an Anti-tubercular Fatty Acid Analogue
Sakallioglu, I. T., Maroli, A. S., Leite, A. D. L., Marshall, D. D., Evans, B. W., Zinniel, D. K., Dussault, P. H., Barletta, R. G., & Powers, R. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.2c08238 · Cited by 11
Song, Q., Guo, X., Zhang, L., Yang, L., & Lu, X. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.714617 · Cited by 11
“…high cost, multidrug-resistant pulmonary tuberculosis (MDR-TB, defined as TB strains resistant to at least isoniazid and rifampin) is still one of the main public health problems in tuberculosis prevention and control (Pontali et al., 2019; Harding, 2020; Migliori et al., 2020; Singh et al., 2020).”
BackgroundZhang, F., Zhang, F., Qin, M., & Li, L. (2024) · Microbial Pathogenesis · doi:10.1016/j.micpath.2024.107003 · Cited by 11
Jiang, G., Liu, R., Xue, Y., Ge, Q., Nie, L., Lv, Z., Kong, Z., Shi, J., Chen, H., Li, H., et al. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s499816 · Cited by 10
Стосман, К. И., Сивак, К. В., Александров, А. Г., Buzitskaya, Z. V., Rassokha, Т. A., & Stukova, M. (2022) · Drug Research · doi:10.1055/a-1771-5985 · Cited by 10
CanB, a Druggable Cellular Target in Mycobacterium tuberculosis
Degiacomi, G., Gianibbi, B., Recchia, D., Stelitano, G., Truglio, G. I., Marra, P., Stamilla, A., Makarov, V., Chiarelli, L. R., Manetti, F., et al. (2023) · ACS Omega · doi:10.1021/acsomega.3c02311 · Cited by 9
Akinnuwesi, A., Egieyeh, S. A., & Cloete, R. E. A. (2023) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2023.1254656 · Cited by 9
Gao, Q., Si, Y., Zheng, T., Li, X., & Wu, P. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.4c06304 · Cited by 9
Fekadu, G., Tolossa, T., Bekele, F., Chen, X., He, Y., Yu, J., Yi, X., Liu, M., Fetensa, G., Dugassa, D., et al. (2025) · BMJ Global Health · doi:10.1136/bmjgh-2024-018220 · Cited by 14
Liu, J., Pang, Y., Li, W., Sun, J., He, Y., Guo, Y., & Dong, J. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01892-24 · Cited by 9
Wang, S., Zhang, J., Hameed, H. M. A., Ding, J., Guan, P., Fang, X., Peng, J., Su, B., Ma, S., Tan, Y., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02809-23 · Cited by 9
Li, P., Wang, B., Chen, X., Lin, Z., Li, G., Lu, Y., & Huang, H. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.106250 · Cited by 9
Ndiaye, M. D., Ranaivomanana, P. P., Rasoloharimanana, L. T., Rasolofo, V., Ratovoson, R., Herindrainy, P., Rakotonirina, J., Schoenhals, M. J., Hoffmann, J., & Rakotosamimanana, N. (2022) · Scientific Reports · doi:10.1038/s41598-022-25236-9 · Cited by 9
Desfontaine, V., Guinchard, S., Marques, S., Vocat, A., Moulfi, F., Versace, F., Pitteloud, J., Ivanyuk, A., Bardinet, C., Makarov, V., et al. (2022) · Journal of Chromatography B · doi:10.1016/j.jchromb.2022.123555 · Cited by 9
Parums, D. V. (2024) · Medical Science Monitor · doi:10.12659/msm.945583 · Cited by 9
“Due to media attention and focused public health alerts, there has been awareness of the rates of tuberculosis (TB) and multi-drug-resistant TB (MDR TB) have recently increased, and new drug treatment combinations and molecular therapeutic approaches are in development [4,5].”
BackgroundSimanjuntak, A. M., Deanasa, R. S., Afladhanti, P. M., Yovi, I., Suyanto, S., Anggraini, D., & Rosdiana, D. (2023) · Narra J · doi:10.52225/narra.v3i3.402 · Cited by 8
“In short, in 2022 WHO recommendation, pretomanid was added, and the short-term treatment period (9 to 11 month) was reduced to 6 months only [7,8].”
BackgroundWei, J., Wang, Q., Wang, J., Ma, L., Huang, M., Wang, J., Du, Y., Cai, B., Shi, W., Li, Q., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf020 · Cited by 8
“In 2020 the WHO recommended a 9-to 12-month all-oral regimen incorporating bedaquiline (BDQ) in place of injectable drugs for eligible patients [8].”
Zhang, R., Luo, S., Wang, N., Zhang, H., & Wu, X. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s408986 · Cited by 8
“Bedaquiline (BDQ), clofazimine (CFZ), linezolid (LZD), delamanid (DLM), and pretomanid (PA-824) have been recommended by the WHO for the treatment of multidrug-resistant tuberculosis.(10) In recent years, some studies have attempted to use bedaquiline, clofazimine, and linezolid for NTM.”
BackgroundChildhood Tuberculosis in Mongolia: Trends and Estimates, 2010-2030
Zanaa, A., Paramita, S. A., Erdenee, O., Tsolmon, B., Purevdagva, A., Yamazaki, C., Uchida, M., & Hamazaki, K. (2022) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2022.j034 · Cited by 8
Spatiotemporal perspectives on tuberculosis chemotherapy
Zhu, J., Liu, Y. J., & Fortune, S. M. (2023) · Current Opinion in Microbiology · doi:10.1016/j.mib.2023.102266 · Cited by 8
Metadata
- Authors
- Mirzayev, F., Viney, K., Linh, N. N., Gonzalez-Angulo, L., Gegia, M., Jaramillo, E., Zignol, M., & Kasaeva, T.
- Affiliations
- World Health Organization (CH)
- Corresponding author
- Mirzayev, Fuad
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2020-11-26
- Volume
- 57
- Issue
- 6
- Pages
- 2003300
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- PMC
- PMC8176349
- OpenAlex
- W3108150642
- Cited by
- 301
- References
- 23
- Citations by year
- 2026: 31 · 2025: 53 · 2024: 43 · 2023: 88 · 2022: 64 · 2021: 22
- FWCI
- 2.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- European Respiratory Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- United States Agency for International Development
- Russian Federation
- Unitaid
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- drug-resistant tuberculosis, multidrug-resistant tuberculosis, rifampicin-resistant tuberculosis, bedaquiline, pretomanid, linezolid, delamanid, fluoroquinolone resistance, treatment duration, WHO treatment recommendations, antimicrobial resistance
- MeSH terms
- Linezolid, Antitubercular Agents, Drug Therapy, Combination, Female, Humans, Pregnancy, World Health Organization, Tuberculosis, Multidrug-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
